A Double-blind, Randomized, Placebo Controlled, Combined Single (Part A) and Multiple (Part B, C) Ascending Dose, Phase 1 Study to Investigate the Safety, Tolerability and Pharmacokinetic and Pharmacodynamics Following Subcutaneous Injections of PG-102(MG12) in Healthy Adult and Obesity Participants
Latest Information Update: 13 May 2025
At a glance
- Drugs PG 102 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Progene
Most Recent Events
- 06 May 2025 Status changed from recruiting to completed.
- 07 Nov 2024 Planned End Date changed from 26 Jun 2024 to 17 Oct 2026.
- 07 Nov 2024 Planned primary completion date changed from 26 Jun 2024 to 4 Feb 2026.